Suven Pharma Q3 2025 performance

**Performance** \- 40% YoY revenue growth in Q3 FY25, reflecting strong market demand. \- 2X increase in incoming project queries, reflecting Suven's increased credibility in the CDMO arena. \- ₹2.3 billion CAPEX is spent to invest for the future, providing scalability and competitiveness. \- 29% API revenue growth, reflecting cost leadership and backward integration leadership. \- 100+% revenue growth in Pharma CDMO revenue year-over-year, reflecting robust industry pickup. \- 400 crores CAPEX outlay in PPE (property, plant, and equipment) for driving future output capacity. **On the charts** Daily TF Demand Zone - 930 - 980 Weekly TF Demand Zone - 810 - 870 Monthly + Weekly Demand zone - 675 - 600 Disclaimer :- This post is just for educational purpose and not a buy/sell recommendation. Please do your own research too.